Routine health checks for heart disease risk did not recover fully after the pandemic

Plus, news on No­var­tis’ re­cent­ly-ap­proved ip­ta­co­pan and Acurx’s an­tibi­ot­ic. Af­fimed drops some in­di­ca­tions from PhI/IIa tri­al: As the biotech re­ports promis­ing mid-stage da­ta for its

Madri­gal Phar­ma­ceu­ti­cals’ NASH drug won an ac­cel­er­at­ed ap­proval on Thurs­day, be­com­ing the first treat­ment for a liv­er dis­ease that for years has vexed sci­en­tists and

The EC granted approval for Bristol Myers Squibb’s Camzyosb based on the positive safety and efficacy data from two Phase III trials. Credit: Bristol-Myers Squibb